Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity

Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity

The escalating global prevalence of type-2 diabetes (T2D) and obesity necessitates the development of novel oral medications. Agonism at G-protein coupled receptor-119 (GPR119) has been recognized for modulation of metabolic homeostasis in T2D, obesity, and fatty liver disease. However, off-target e...

Full description

Bibliographic Details
Main Authors: Patil, Mohan, Casari, Ilaria, Thapa, Dinesh, Warne, Leon, Dallerba, Elena, Massi, Max, Carlessi, Rodrigo, Falasca, M.
Format: Journal Article
Language:English
Published: 2024
Subjects:
GLP-1
Synthetic GPR119 agonists
obesity
pharmacodynamics
pharmacokinetics
toxicity
type-2 diabetes
Animals
Humans
Male
Mice
Caco-2 Cells
Diabetes Mellitus, Type 2
Enteroendocrine Cells
Glucagon-Like Peptide 1
Hypoglycemic Agents
Mice, Inbred C57BL
Obesity
Receptors, G-Protein-Coupled
Online Access:http://hdl.handle.net/20.500.11937/96028

Internet

http://hdl.handle.net/20.500.11937/96028

Similar Items